← Eichor
Study identifier: NCT06430502 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours

Condition: Cancer · PD-L1 Gene Mutation  ·  Sponsor: Wuxi People's Hospital

PhaseNA
Planned participants200
Who can joinAll sexes, 18 Years to 85 Years
Healthy volunteersNo

About this study

This study is intended to investigate the clinical efficacy of TTV vaccine combined with PD-1/PD-L1 inhibitor in the treatment of relapsed and refractory advanced solid tumours from a clinical perspective.

This description comes directly from the study's public registry record.

Talk to the study team

Peihua Lu  ·  0510-85350495  ·  lphty1_1@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Wuxi People's HospitalWuxi, Jiangsu, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06430502